The Centers for Disease Control and Prevention (CDC) today released the results of the first real-Life efficacy trial of the COVID-19 vaccine. The study found that regardless of the presence or absence of symptoms, protection against infection reached 80 percent after a single dose of Pfizer or Modena vaccine, rising to 90 percent after completing two doses.
CDC conducted the trial from Dec. 14 of last year to March 13 of this year with 3,950 people whose jobs are more likely to be exposed to coronavirus disease 2019 (COVID-19, Wuhan pneumonia), including healthcare workers, first responders and other people essential to the functioning of society.
Regardless of the presence or absence of symptoms, test subjects were required to perform their own nasal swab sampling weekly and return to the laboratory for RT-PCR nucleic acid virus testing. Thus, even asymptomatic infected individuals can be detected.
The results of the trial found that of the 2,479 people who completed the two doses of Pfizer or Moderna vaccine, only three were diagnosed during the trial; of the 477 people who received only a single dose, eight were diagnosed. In comparison, of the 994 unvaccinated subjects, 161 were diagnosed.
The results of the trial showed that the risk of infection was significantly reduced by 80% after two weeks of a single dose of Pfizer or Modena vaccine, and by 90% after two weeks of the recommended second dose.
The CDC said the study results indicate that both the Pfizer and Modena vaccines are effective in reducing the risk of infection, not just providing protection against symptomatic infections.
The CDC’s report released today should clear up any concerns that the vaccine only protects against symptomatic infections, meaning that people who have been vaccinated may still be infected, but will not develop symptoms and thus unknowingly spread the virus.
According to the CDC, as of 4 p.m. today, 52.61 million people in the U.S. have been vaccinated, accounting for 15.8 percent of the total population, of which nearly 94 percent were vaccinated with Pfizer or Modena, and only about 6 percent were vaccinated with the Johnson & Johnson single-dose vaccine, which received emergency use authorization from the U.S. Food and Drug Administration (FDA) in late February.
Recent Comments